- 中文名称
Anti-Human DLK-1/Pref-1
- 英文名字
- Anti-Human DLK-1/Pref-1
- 供应商
- ReliaTech
- 产品货号
- 102-PA137S
- 产品报价
- ￥询价/100ug
- 产品说明书
- 点击查看
- 购买方式
- 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868
- 产品新闻
- 背景资料
- Delta-like 1 (DLK1), also known as Pref-1 and FA1, is a transmembrane protein pertaining to the epidermal growth factor superfamily. DLK1 affects several differentiation processes, including adipogenesis, muscular and neuronal differentiation, bone differentiation, and haematopoiesis. Several reports support that DLK1 may operate as a non-canonical ligand of the NOTCH pathway. Since the NOTCH signaling pathway is essential for vascular development and physiology by controlling angiogenesis in pre- and post-natal life, it was reasoned that DLK1 could contribute to regulate this process in adult endothelial cells through the interaction with NOTCH receptors. It was found that overexpression of DLK1 inhibits migration and angiotube formation in mammalian vascular endothelial cells and disrupts normal embryonic vascularization in zebrafish. Genetic ablation of DLK1 in mice is associated with increased angiogenesis in vitro and with focal areas of retinal hyper-vascularization. Specific knockdown of the orthologous Dlk1 of zebrafish results in ectopic angiogenesis. Moreover, in a tumor angiogenesis model in zebrafish, suppression of Dlk1 promotes vessel migration towards the tumor cell mass. It was also found that the NOTCH signaling pathway is targeted by DLK1 in the context of angiogenesis and that DLK1 antagonizes NOTCH-dependent signaling in endothelial cells, while, in contrast, this signaling is enhanced in Dlk1-null mice. Collectively, these results revealed a previously unknown role for DLK1 in the vasculature as a regulator of NOTCH-mediated angiogenesis.
- 应用类型
- WB
- 免疫原
- 该Anti-Human DLK-1/Pref-1的详细信息查看ReliaTech提供的产品说明书。
- 来源宿主
- Rabbit
- 反应性
- 该Anti-Human DLK-1/Pref-1的详细信息查看ReliaTech提供的产品说明书。
- 保存建议
- 该Anti-Human DLK-1/Pref-1的详细信息查看ReliaTech提供的产品说明书。
- 其他
- ReliaTech全称为受体配体技术有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，总部位于德国不伦瑞克，是一家后基因组生物技术公司。ReliaTech主要专注于受体和配体的发现与研究。此外，ReliaTech也开发应用于血管与淋巴管生成研究的相关高品质试剂。目前ReliaTech提供近2800款产品，产品线主要包括重组蛋白(细胞因子、生长因子、可溶性受体)、抗体、ELISA试剂盒等。
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
